The mechanisms mediating T-cell depletion plus 15-deoxyspergualin (DSG)-induced prolonged allograft survival or tolerance are uncertain. The purpose of this study is to evaluate the role of IL-4 and IL-10 in prolonged allograft survival induced by T-cell depletion plus DSG. MHC mismatched skin allograft transplantation was performed, using wild-type and three separate knockout (i.e., IL-4−/−, Stat6−/−, or IL-10−/ −) mice as recipients. Induction therapy consisted of T-cell depletion and or brief course of DSG. The data demonstrate that monotherapy with T-cell-depleting mAbs or DSG prolonged skin allograft survival, compared to controls, in wild-type Balb/c recipients [median survival time (MST) = 25 and 21 vs. 10 days, p < 0.007]. T-cell depletion plus DSG further augmented skin allograft survival in wild-type animals relative to monotherapy (MST = 35 days vs. 25 and 21 days, p < 0.006 vs. mAbs or DSG only), and was equally effective in IL-4−/− and Stat6−/− recipients. In contrast, combined therapy was no better than monotherapy in IL-10−/− animals (p > 0.05). Furthermore, skin allograft survival after combined therapy was shorter in IL-10−/− versus wild-type recipients (MST 20 and 41 days, respectively, p < 0.001). IL-4-mediated signaling through Stat6 is dispensable for prolonged allograft survival induced by T-cell depletion plus DSG. In contrast, IL-10 appears to be important for prolonged allograft survival induced by combined therapy in this model.
INTRODUCTION
latory T cells that secrete IL-10 (11). Anti-T cell antibodies combined with the immunosuppressant deoxyspergualin (DSG) has achieved prolonged allograft survival Many studies have suggested that IL-4 and IL-10 are important in promoting long-term allograft acceptance.
and tolerance in experimental transplantation (18, 29) . DSG, a synthetic polyamine that binds to heat shock For example, neonatal tolerance can be induced in IL-4−/− mice but not in IL-4−/− and IL-13−/− double muproteins with the C-terminal motif EEVD (20), has been shown to be effective in preventing and/or reversing tant mice, indicating that IL-4-mediated signaling must be completely disrupted to block the induction of neonaacute rejection in clinical solid organ transplantation (3, 14, 21) and also in the treatment of antibody-mediated tal tolerance (13) . Addition of anti-IL-4 mAb or anti-IL-10 mAb to anti-CD2 plus anti-CD3 treatment abrogated acute rejection (22) . In addition, beneficial effects have been reported for DSG in the treatment of experimental tolerance and resulted in lower graft survivals (23) . Also, an essential role for IL-10 was shown for tolerance and clinical autoimmune disease (6, 9, 27) . Campath-1-induced T-cell depletion plus DSG induction therapy induced to inhaled antigen (1) and for tolerance in human severe combined immunodeficiency (SCID) pawas examined in clinical kidney transplant patients recently (15) . T-cell depletion combined with DSG has tients after allogeneic bone marrow stem cell transplantation (5) . Prolonged allograft survival induced by T-cell an additive or synergistic effect in promoting allograft survival in mice (2, 18, 28) and rats (24) . The role of type depletion was dependent on IL-10 (26) and tolerance to cardiac allografts induced by T-cell depletion plus donor 2 cytokines in prolonged survival/tolerance induced by T-cell depletion plus DSG is uncertain. Thus, we asblood transfusion involved donor antigen-specific regu-714 ASIEDU ET AL.
sessed the role of IL-4 and IL-10 in prolongation of skin were used, DSG was administered about 2 h before Tcell-depleting mAbs. allograft survival induced by peritransplant T-cell depletion plus DSG.
Skin Transplantation

MATERIALS AND METHODS
Skin grafting was performed as previously described Mice (10) . Briefly, a piece of donor skin (ϳ1.5 cm 2 ) was placed on a graft bed made on the recipient's flank and Wild-type, IL-4−/− and Stat6−/− mice on a Balb/c sutured in place. A plaster cast jacket was used to probackground, and wild type, IL-10−/− mice on a C57BL/ tect the graft until day +7. Allografts were subsequently 6 background were obtained from Jackson Laboratories examined every other day until rejection. Rejection was (Bethesda, MD). All animals were housed in the pathodefined as complete destruction of the graft epidermis gen-free facility at the University of Alabama at Biras determined by macroscopic observation. In a few mingham (UAB). The animals used were matched for cases with the longest skin allograft survivals, rejection age (8-12 weeks) and sex (male). All protocols were was scored as shrinkage of the graft to 20% of its initial approved by the UAB Institutional Animal Care and Use size. Committee.
IL-10 Measurements and Treatment Study Groups
C57BL/6 wild-type mice treated with anti-CD4 and Five groups of mice were studied. In the first group anti-CD8 plus DSG and transplanted with allogeneic skin allografts from wild-type C57BL/6 mice were skin grafts were sacrificed at 5, 10, and 15 days posttransplanted to wild-type Balb/c recipients. Balb/c ILtransplant. Blood was obtained from anesthetized mice 4−/− and Balb/c Stat6−/− mice constituted the second by cardiac puncture and serum was stored at −20°C. ILand third recipient groups, respectively, and received 10 levels were determined by ELISA (BioScience Interskin allografts from C57BL/6 mice to determine whether national, CA). A separate group of transplanted IL-10−/ IL-4 is necessary for prolongation of allograft survival.
− C57BL/6 recipients were given combined therapy plus It was necessary to test both of these recipients because intraperitoneal IL-10 posttransplant to further assess the of the possibility that IL-13 may compensate for IL-4 role of this cytokine in skin allograft survival. Mice redeficiency in IL-4−/− animals by signaling through ceived 0.01 µg of IL-10 every other day beginning from Stat6, which is downstream of both IL-4 and IL-13 postday of transplantation up to day 15 (short therapy, ST) receptor signal pathways (13) . Finally in the fourth and or until graft rejection (prolonged therapy, PT). Recomfifth groups, wild-type Balb/c skin allografts were transbinant mouse IL-10 (R&D Systems, Minneapolis, MN), planted to wild-type and IL-10−/− C57BL/6 recipients, mouse IL-10Fc (Axxora, San Diego, CA), and rhesus respectively, to evaluate the role of IL-10 in graft sur-IL-10Fc (4) were tested in this model. vival. Thus, a total of three different knockout mice, lacking IL-4, Stat6 (on Balb/c strain background), or ILStatistical Analysis 10 (on C57BL/6 strain background) were used in these Graft survival times for different treatment groups studies.
were compared using the Wilcoxon test. Differences Animal Treatment were considered statistically significant when p < 0.05. Data analyses were performed using Statgraphics softFour treatment protocols were used within each study group: no treatment, T-cell depletion only, DSG only, ware (Manugistics Inc., Rockville, MD). and combined therapy (T-cell depletion plus DSG). To RESULTS deplete T cells, 250 µg GK1.5 (anti-CD4) and 250 µg 2.43 (anti-CD8) mAbs were given IP on days −1 and Without treatment, wild-type Balb/c recipients rejected skin allografts from C57BL/6 donors promptly +2 relative to the day of transplantation. This treatment regimen typically depleted T cells in blood, spleen, and with a median survival time (MST) of 10 days (Fig. 1 ). T-cell-depleting mAbs increased the MST of skin allolymph nodes to 1.9%, 1.6%, and 2.2%, respectively, compared to untreated controls. Blood, spleen, and grafts to 25 days (p = 0.006 vs. controls). Monotherapy with DSG also resulted in a significant increase of MST, lymph node T cells recovered to pretreatment levels between days 65 and 80. DSG (2.5 mg/kg, subcutaneous to 21 days (p = 0.003 vs. controls). T-cell depletion plus DSG further augmented skin allograft survival comroute) (Novartis, Basel, Switzerland) was freshly rehydrated in PBS and administered daily beginning on day pared to monotherapy (MST = 35 days, p < 0.003 vs. monotherapy). Therefore, combined therapy increased −1 to day +13 relative to the day of transplantation (day 0). In cases where both DSG and T-cell-depleting mAbs skin allograft survival in wild-type recipients. T-cell depletion plus DSG significantly prolonged skin allograft survival in wild-type recipients. Treatments and transplantation were performed as described in Materials and Methods. Survival of C57BL/6 skin allografts in the following groups of wild-type Balb/c mice: no treatment (n = 7); mAb (n = 7); DSG (n = 5); and DSG/mAb (n = 10).
To determine the role of TH2 signaling pathways in ment with T-cell-depleting mAbs or DSG alone resulted in significant increases in median skin allograft survival the observed increased graft survival, we performed a similar experiment using IL-4−/− and Stat6−/− animals compared to untreated animals (MST = 25 and 20 days, respectively, p < 0.008 vs. controls) (Fig. 4B ). Of note, as recipients. The pattern of skin allograft survival observed in IL-4−/− and Stat6−/− recipients was similar to however, combined therapy achieved an MST of only 20 days in IL-10−/− recipients, which is no better than that described above for wild-type animals. Monotherapy resulted in significantly prolonged MST compared treatment with either T-cell-depleting mAbs or DSG (p > 0.1) (Fig. 4B) . Furthermore, the MST achieved by to no treatment (p < 0.03) (Fig. 2) . Combined therapy achieved skin allograft survival that was significantly combined therapy in the IL-10−/− recipients was only 50% of that observed in wild-type recipients (Fig. 4C ). better than that obtained after monotherapy in both groups of knock out recipients (p < 0.006). The overlapThus, T-cell depletion plus DSG failed to prolong skin allograft survival in IL-10−/− mice compared to monoping survival plots in Figure 3 demonstrate that combined therapy is as effective in wild-type recipients as it therapy, suggesting a role for IL-10 in mediating the additive effect of combined therapy in this model. is in IL-4−/− and Stat6−/− animals (p > 0.6), suggesting that IL-4/IL-13-mediated signal transduction via Stat6 is
In view of the observation that IL-10 is required for combined therapy to prolong allograft survival, we wonnot required for prolongation of allograft survival induced by T-cell depletion plus DSG. dered whether IL-10 is elevated in wild-type recipients treated with T-cell-depleting mAbs plus DSG. Thus, we To examine the role of IL-10 in prolonged allograft survival induced by the combined treatment, Balb/c skin tested serum samples from C57BL/6 recipients treated with T-cell-depleting mAbs plus DSG for IL-10. Algrafts were transplanted onto wild-type or IL-10−/− C57BL/6 recipients. Although Balb/c → C57BL/6 is pothough IL-10 was detectable in the pretransplant serum, none was detected at any time tested posttransplantation tentially a more stringent combination than C57BL/6 → Balb/c, median graft survival time obtained in the for- (Table 1 ), although we only tested serum samples taken up to 2 weeks posttransplant. Thus, combined therapy mer combination (41 days) (Fig. 4A ) was similar to that obtained in the latter combination (35 days, p > 0.05) was not associated with early elevated levels of IL-10 in the peripheral circulation. Next, we determined whether (Fig. 1) . Thus, differences in the stringency of the strain combinations studied are apparently not a factor here.
exogenous IL-10 could restore the additive effect of combined therapy in IL-10-deficient recipients. ShortCombined therapy significantly prolonged skin allograft survival in wild-type C57BL/6 recipients (MST = 41 term or prolonged systemic administration of mouse IL-10, mouse IL-10Fc, or rhesus IL-10Fc had no beneficial days) compared to monotherapy with T-cell-depleting mAbs or DSG (MST = 29 and 21 days, respectively, p < effect on allograft survival induced by combined therapy in IL-10−/− recipients ( Fig. 5 and data not shown). 0.01) (Fig. 4A) . In the case of IL-10−/− recipients, treat- Because combined therapy produces divergent effects in prolonged skin allograft survival in wild-type recipients relative to either treatment alone. Here we examined IL-4-and Stat6-deficient mice versus IL-10−/− mice, the tendency towards type 1 immunity is not the reason for whether IL-4-or IL-10-dependent signaling mediates prolonged allograft survival induced by T-cell depletion the failure of T-cell depletion plus DSG treatment to prolong allograft survival beyond that of monotherapy plus DSG therapy. Our data suggest that prolongation of skin allograft survival by T-cell depletion plus DSG in IL-10−/− recipients. We have demonstrated that DSG and T-cell-depleting therapy requires IL-10 but is independent of IL-4/IL-13-mAbs monotherapy prolonged allograft survival to a similar extent in IL-10-deficient and wild-type recipients. This finding contrasts with the previous reports that Table 1 . Serum IL-10 Levels allograft acceptance induced by T-cell depletion was shorter in IL-10−/− recipients relative to wild-type aniTime Serum IL-10 (pg/ml) mals (25, 26) . The difference between our results and Raisanen-Sokolowski et al. used 500 µg of each antimay be immunostimulatory at high doses (7, 17) , it is also possible that the doses of IL-10 administered in our body on days 1-4 posttransplantation, followed by the same dose every week up to day 30. The failure of comstudies are high. Further studies are in progress to examine the effect of lower doses of IL-10 in this model. ILbined therapy to prolong allograft acceptance beyond that of monotherapy implies that IL-10 is important for 10 is produced by a variety of Th2 cells, monocytes/ macrophages, B cells, and dendritic cells (12, 19) . Studthe effect of combined therapy.
In addition, the MST achieved by combined therapy ies are also in process to identify cells producing IL-10 by intracellular staining and flow cytometry in wild-type in IL-10−/− mice was half of that observed in similarly treated wild-type recipients (20 days vs. 41 days, p = recipients given combined therapy. We have demonstrated that while IL-4/IL-13-medi-0.0001). This finding confirms the importance of IL-10 in this model. The absence of detectable levels of sysated signal transduction is dispensable for prolongation of allograft acceptance induced by T-cell depletion plus temic IL-10 does not exclude a requirement for IL-10 in local microenvironments such as at cell-cell junctions, DSG, IL-10 is important in this model. Interestingly, long-term tolerance to islet allografts in nonhuman priintragraft site, and draining lymph node. IL-10 may be required intracellularly and/or locally in the graft or at mates treated briefly with T-cell-depleting anti-CD3 immunotoxin plus DSG is associated with elevated serum the draining lymph nodes as opposed to the systemic circulation. In line with a paracrine mode of action for IL-10, suggesting a role for IL-10 in the induction and or maintenance of tolerance (29) . The mouse model is IL-10, various doses of exogenous mouse IL-10, mouse IL-10Fc, and rhesus IL-10Fc had no beneficial effect different in that serum IL-10 is not elevated; however, IL-10 appears to be important for allograft acceptance on skin allograft survival in IL-10−/− recipients given combined therapy. This suggests that IL-10 may be proin both models. We postulate that failure to induce IL-10-dependent immune regulation may render combined duced by a particular cell subset and act in an autocrine or paracrine manner in tight junctions or synapses that therapy ineffective in IL-10−/− animals. Perhaps both systemic IL-10 and local (in the graft bed) IL-10 may are inaccessible to exogenously administered IL-10. It is possible that IL-10 is required for the function of a be required to restore the efficacy of T-cell depletion plus DSG in IL-10−/− animals. regulatory T-cell subset (e.g., NKT cell or CD4 + CD25 + T cell) that mediates prolonged allograft survival in- 
